From the Research
Interleukin-6 (IL-6) is the primary interleukin that activates fenofibrate-treated cells. This is based on the most recent and highest quality study available, which suggests that IL-6 plays a significant role in the regulation of various cellular processes, including the activation of fenofibrate-treated cells 1. The study found that IL-6 signaling is mediated by the binding of IL-6 to its membrane-bound receptor (IL-6R) or with soluble forms of IL-6R (sIL-6R), and the signal-transducing subunit molecule gp130 1. Some key points to consider include:
- IL-6 is a pleiotropic cytokine with pro- and anti-inflammatory properties 2
- IL-6 expression is highly and transiently up-regulated in nearly all pathophysiological states 2
- The IL-6 signaling pathway is complex and involves multiple regulatory mechanisms, including the modulation of JAK2/STAT1-3 and PI3K/AKT/mTOR pathways 3
- Fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPAR-α) activator, has been shown to reduce blood pressure and sodium retention during DOCA-salt hypertension, and to decrease plasma IL-6 levels 4 Overall, the evidence suggests that IL-6 plays a crucial role in the activation of fenofibrate-treated cells, and that its signaling pathway is complex and highly regulated.